Clinical trial · Interventional
REcovery of Left Ventricular Dysfunction in CAncer Patients (RECAP Trial)
NCT02543294CI-TRIAL-00043214completedN/AResults postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this clinical trial is to learn if heart function remains normal after stopping heart failure medication in patients who have received chemotherapy.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer Treatment Induced Left Ventricular Dysfunction | — | UNRESOLVED | — |
| Heart Failure | — | UNRESOLVED | — |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Echocardiograms | Device | — | UNRESOLVED |
| Electrocardiogram | Device | — | UNRESOLVED |
| Symptom Questionnaire | Behavioral | — | UNRESOLVED |
| Telephone Follow-Up | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- Anthracycline Treatment Group
- description
- Participants undergo echocardiograms with contrast done at baseline and at months 2, 4, 6, 12, 18, and 30. Electrocardiogram performed at baseline. Symptom questionnaire completed at baseline and at months 1, 2, 4, 6, 12, 18, and 30. Telephone follow-up by study staff at months 3 and 5.
- interventionNames
- Device: Echocardiograms
- Device: Electrocardiogram
- Behavioral: Symptom Questionnaire
- Behavioral: Telephone Follow-Up
- type
- EXPERIMENTAL
- label
- Herceptin Treatment Group
- description
- Participants undergo echocardiograms with contrast done at baseline and at months 2, 4, 6, 12, 18, and 30. Electrocardiogram performed at baseline. Symptom questionnaire completed at baseline and at months 1, 2, 4, 6, 12, 18, and 30. Telephone follow-up by study staff at months 3 and 5.
- interventionNames
- Device: Echocardiograms
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Cancer survivors with no evidence of disease for at least 6 months as determined by the oncologist and no longer receiving cancer treatment. 2. Prior diagnosis of CILVD with recovered LVEF (i.e. improved to \> 50%) for at least 6 months with recommended HF medications (ACE-I or ARB and/or B-blocker). 3. Absence of other causes of cardiomyopathy (e.g. ischemia, hypertension, amyloidosis, or hemochromatosis) per chart review of the clinician's documentation 4. Documented normal LVEF for at least 6 months after the initiation of recommended HF therapy. 5. Age 18 - 80 years. HF clinical guidelines is supported by evidenced-based data from clinical trials which includes individuals up to 80 years of age. 6. Residence within the United States. 7. Ability to read and write English, because the MD Anderson Symptom Inventory -Heart Failure (MDASI-HF) instrument (Fadol et al., 2008) has been validated in English only. Exclusion Criteria: 1. Participants will be excluded if they have a recurrence that requires anti-cancer treatment. 2. Have a documented history of hypertension, coronary artery disease, myocardial infarction, diabetes mellitus, amyloidosis or hemochromatosis. 3. Exhibiting HF symptoms (e.g. shortness of breath, edema). 4. Pregnancy
References
Publications (0)
Data not yet available
No reference posted for this study.